GSK plc. (GSK,GSK.L) and Alector, Inc. announced results from the INFRONT-3 clinical trial evaluating latozinemab in individuals with frontotemporal dementia caused by a mutation in the progranulin gene (FTD-GRN).
While treatment with latozinemab achieved a statistically significant improvement in the biomarker co-primary endpoint—plasma progranulin (PGRN) concentrations—it did not demonstrate clinical benefit in slowing disease progression. Additionally, no treatment-related effects were observed across secondary and exploratory endpoints.
Preliminary safety data have not revealed any major concerns, though further analysis is ongoing. Based on the overall findings, both the open-label extension and continuation study for latozinemab will be discontinued.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.